Business
Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston
PONTE VEDRA, Fla., June 1, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Cadrenal or the Company) (Nasdaq: CVKD) a biopharmaceutical company developing
About this update from Cadrenal Therapeutics, Inc.
[{"type":"text","content":"PONTE VEDRA, Fla., June 1, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Cadrenal or the Company) (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, announced today that the company will participate in investor and partnering meetings at the BIO International Convention being held June 5-8, 2023 in Boston.\n\n \n \n \n \n \n \n\n \nDuring the convention, members of the Cadrenal management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones. \n\"Our clinical development pipeline offers the potential to address the need for prevention of thrombotic and thromboembolic events (blood clots) that are not adequately addressed by current treatment options,\" said Quang Pham, Chairman, Chief Executive Officer, and Founder of Cadrenal. \"Patients with chronic kidney disease, blood clotting disorders, and those with implantable medical devices could benefit from a more stable and readily reversible anticoagulation agent. Our goal at Cadrenal is to maximize the value of our pipeline for patients. BIO International Convention provides an ideal venue for such conversations, and we look forward to actively engaging with biopharma representatives and investors in attendance.\"\nMeetings with conference attendees can be scheduled through the BIO One-on-One Partnering system: https://www.bio.org/events/bio-international-convention/one-one-partneringtm, or by emailing Cadrenal's corporate contacts using the information provided at the end of this press release.\nSafe Harbor Statement\nAny statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \"forward-looking statements.\" These statements include statements regarding the Company's clinical development pipeline offering the potential to address the need for the prevention of thrombotic and thromboembolic events (blood clots) that are not adequately addressed by current treatment options, patients with chronic kidney disease, blood clotting disorders and those with implantable ...